Comparative Benchmarking
In the context of the broader market, CLDI competes directly with industry leaders such as ENSC and HCWB. With a market capitalization of $2.61M, it holds a leading position in the sector. When comparing efficiency, CLDI's gross margin of N/A stands against ENSC's 100.00% and HCWB's 20.00%. Such benchmarking helps identify whether Calidi Biotherapeutics Inc is trading at a premium or discount relative to its financial performance.
